217 related articles for article (PubMed ID: 18190686)
1. Preclinical evaluation of lime juice as a topical microbicide candidate.
Fletcher PS; Harman SJ; Boothe AR; Doncel GF; Shattock RJ
Retrovirology; 2008 Jan; 5():3. PubMed ID: 18190686
[TBL] [Abstract][Full Text] [Related]
2. Six-day randomized safety trial of intravaginal lime juice.
Mauck CK; Ballagh SA; Creinin MD; Weiner DH; Doncel GF; Fichorova RN; Schwartz JL; Chandra N; Callahan MM
J Acquir Immune Defic Syndr; 2008 Nov; 49(3):243-50. PubMed ID: 18845958
[TBL] [Abstract][Full Text] [Related]
3. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
[TBL] [Abstract][Full Text] [Related]
4. Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.
Trifonova RT; Pasicznyk JM; Fichorova RN
Antimicrob Agents Chemother; 2006 Dec; 50(12):4005-10. PubMed ID: 17030562
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
Aranha CC; Gupta SM; Reddy KV
Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.
Harman S; Herrera C; Armanasco N; Nuttall J; Shattock RJ
Antimicrob Agents Chemother; 2012 May; 56(5):2347-56. PubMed ID: 22330930
[TBL] [Abstract][Full Text] [Related]
8. Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.
Yang J; Li L; Jin H; Tan S; Qiu J; Yang L; Ding Y; Jiang ZH; Jiang S; Liu S
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1498-508. PubMed ID: 22867271
[TBL] [Abstract][Full Text] [Related]
9. Lime juice as a candidate microbicide? An open-label safety trial of 10% and 20% lime juice used vaginally.
Hemmerling A; Potts M; Walsh J; Young-Holt B; Whaley K; Stefanski DA
J Womens Health (Larchmt); 2007 Sep; 16(7):1041-51. PubMed ID: 17903081
[TBL] [Abstract][Full Text] [Related]
10. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture.
Cummins JE; Guarner J; Flowers L; Guenthner PC; Bartlett J; Morken T; Grohskopf LA; Paxton L; Dezzutti CS
Antimicrob Agents Chemother; 2007 May; 51(5):1770-9. PubMed ID: 17353237
[TBL] [Abstract][Full Text] [Related]
11. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct.
Cole AL; Herasimtschuk A; Gupta P; Waring AJ; Lehrer RI; Cole AM
Immunology; 2007 May; 121(1):140-5. PubMed ID: 17250585
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of the viability of vaginal cells (VK2/E6E7) and probiotic Lactobacillus species in lemon juice.
Anukam KC; Reid G
Sex Health; 2009 Mar; 6(1):67-74. PubMed ID: 19254495
[TBL] [Abstract][Full Text] [Related]
13. Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.
Fichorova RN; Zhou F; Ratnam V; Atanassova V; Jiang S; Strick N; Neurath AR
Antimicrob Agents Chemother; 2005 Jan; 49(1):323-35. PubMed ID: 15616312
[TBL] [Abstract][Full Text] [Related]
14. Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G.
Catalone BJ; Miller SR; Ferguson ML; Malamud D; Kish-Catalone T; Thakkar NJ; Krebs FC; Howett MK; Wigdahl B
Biomed Pharmacother; 2005 Sep; 59(8):430-7. PubMed ID: 16154721
[TBL] [Abstract][Full Text] [Related]
15. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity.
Gali Y; Ariën KK; Praet M; Van den Bergh R; Temmerman M; Delezay O; Vanham G
J Virol Methods; 2010 May; 165(2):186-97. PubMed ID: 20138087
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety evaluation of the candidate vaginal microbicide C31G.
Catalone BJ; Kish-Catalone TM; Neely EB; Budgeon LR; Ferguson ML; Stiller C; Miller SR; Malamud D; Krebs FC; Howett MK; Wigdahl B
Antimicrob Agents Chemother; 2005 Apr; 49(4):1509-20. PubMed ID: 15793133
[TBL] [Abstract][Full Text] [Related]
17. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
[TBL] [Abstract][Full Text] [Related]
18. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?
das Neves J; Amiji M; Sarmento B
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2011; 3(4):389-99. PubMed ID: 21506290
[TBL] [Abstract][Full Text] [Related]
19. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro.
O'Connor TJ; Kinchington D; Kangro HO; Jeffries DJ
Int J STD AIDS; 1995; 6(4):267-72. PubMed ID: 7548290
[TBL] [Abstract][Full Text] [Related]
20. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model.
Patton DL; Cosgrove Sweeney YT; Paul KJ
Sex Transm Dis; 2008 Oct; 35(10):889-97. PubMed ID: 18607310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
